Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

MannKind

Nasdaq:MNKD
Snowflake Description

High growth potential with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MNKD
Nasdaq
$225M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • MannKind has significant price volatility in the past 3 months.
MNKD Share Price and Events
7 Day Returns
5%
NasdaqGM:MNKD
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-46.2%
NasdaqGM:MNKD
1.6%
US Biotechs
-9.1%
US Market
MNKD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MannKind (MNKD) 5% -19.1% -22.6% -46.2% -28.4% -96%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • MNKD underperformed the Biotechs industry which returned 1.6% over the past year.
  • MNKD underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
MNKD
Industry
5yr Volatility vs Market
Related Companies

Value

 Is MannKind undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether MannKind is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MannKind has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MannKind. This is due to cash flow or dividend data being unavailable. The share price is $1.06.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MannKind's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MannKind's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:MNKD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.27
NasdaqGM:MNKD Share Price ** NasdaqGM (2020-03-27) in USD $1.06
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MannKind.

NasdaqGM:MNKD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MNKD Share Price ÷ EPS (both in USD)

= 1.06 ÷ -0.27

-3.99x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MannKind is loss making, we can't compare its value to the US Biotechs industry average.
  • MannKind is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does MannKind's expected growth come at a high price?
Raw Data
NasdaqGM:MNKD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.99x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
60.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MannKind, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MannKind's assets?
Raw Data
NasdaqGM:MNKD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.90
NasdaqGM:MNKD Share Price * NasdaqGM (2020-03-27) in USD $1.06
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:MNKD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MNKD Share Price ÷ Book Value per Share (both in USD)

= 1.06 ÷ -0.90

-1.18x

* Primary Listing of MannKind.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MannKind has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at MannKind's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MannKind's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess MannKind's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MannKind has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MannKind expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MannKind expected to grow at an attractive rate?
  • MannKind's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • MannKind's earnings growth is expected to exceed the United States of America market average.
  • MannKind's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:MNKD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:MNKD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 60.8%
NasdaqGM:MNKD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 23.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:MNKD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:MNKD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 202 53 47 3
2023-12-31 162 33 33 3
2022-12-31 140 4 -8 2
2021-12-31 106 -14 -20 5
2020-12-31 66 -47 -45 5
2020-03-28
NasdaqGM:MNKD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 63 -88 -52
2019-09-30 63 -58 -47
2019-06-30 53 -20 -61
2019-03-31 42 -28 -71
2018-12-31 28 -38 -87
2018-09-30 16 -93 -110
2018-06-30 13 -102 -119
2018-03-31 12 -95 -131
2017-12-31 11 -65 -117
2017-09-30 20 -48 -31
2017-06-30 180 -47 129
2017-03-31 178 -39 134

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MannKind's earnings are expected to grow significantly at over 20% yearly.
  • MannKind's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:MNKD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from MannKind Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MNKD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.21 0.29 0.11 3.00
2023-12-31 0.15 0.19 0.11 2.00
2022-12-31 -0.03 0.10 -0.14 3.00
2021-12-31 -0.09 -0.03 -0.15 5.00
2020-12-31 -0.21 -0.18 -0.26 5.00
2020-03-28
NasdaqGM:MNKD Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.27
2019-09-30 -0.26
2019-06-30 -0.35
2019-03-31 -0.44
2018-12-31 -0.60
2018-09-30 -0.83
2018-06-30 -0.98
2018-03-31 -1.19
2017-12-31 -1.13
2017-09-30 -0.31
2017-06-30 1.33
2017-03-31 1.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MannKind will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MannKind's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MannKind has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MannKind performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MannKind's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MannKind does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare MannKind's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MannKind's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
MannKind's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MannKind Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MNKD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 63.04 -51.90 74.67 6.90
2019-09-30 63.08 -47.39 76.92 5.96
2019-06-30 52.95 -61.19 79.65 6.43
2019-03-31 41.84 -71.47 84.77 7.76
2018-12-31 27.86 -86.98 79.72 8.74
2018-09-30 15.76 -110.01 85.02 11.16
2018-06-30 13.33 -118.73 83.35 13.48
2018-03-31 11.60 -131.39 80.19 13.63
2017-12-31 11.15 -117.33 74.96 14.12
2017-09-30 19.62 -30.58 67.01 12.17
2017-06-30 179.93 128.83 62.42 11.73
2017-03-31 177.77 134.21 54.97 18.05
2016-12-31 174.76 125.66 46.93 14.92
2016-09-30 162.35 -205.33 37.81 20.28
2016-06-30 -363.71 35.02 20.70
2016-03-31 -362.66 34.53 19.00
2015-12-31 -368.45 40.96 29.67
2015-09-30 -127.87 43.99 39.02
2015-06-30 -132.53 52.73 53.85
2015-03-31 -176.98 74.63 83.44
2014-12-31 -198.38 79.38 100.24
2014-09-30 -215.52 84.47 111.67
2014-06-30 -229.82 82.86 119.78
2014-03-31 -202.58 64.87 109.50
2013-12-31 -191.49 59.68 109.72
2013-09-30 0.00 -189.69 52.41 106.01
2013-06-30 0.04 -181.70 44.10 104.18
2013-03-31 0.04 -172.16 39.24 103.76

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MannKind has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if MannKind has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MannKind improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MannKind's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MannKind has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MannKind's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MannKind's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MannKind's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • MannKind's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of MannKind's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • MannKind has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MannKind Company Filings, last reported 2 months ago.

NasdaqGM:MNKD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -190.53 118.90 49.88
2019-09-30 -184.71 118.77 50.06
2019-06-30 -196.00 99.99 32.88
2019-03-31 -188.00 102.49 59.29
2018-12-31 -175.08 102.49 71.16
2018-09-30 -205.44 105.48 10.45
2018-06-30 -206.62 129.36 26.18
2018-03-31 -223.21 140.27 26.71
2017-12-31 -214.73 156.82 43.95
2017-09-30 -251.02 165.27 20.09
2017-06-30 -221.24 164.80 43.38
2017-03-31 -198.73 148.96 47.98
2016-12-31 -183.59 148.50 22.90
2016-09-30 -238.69 219.25 35.53
2016-06-30 -366.58 222.57 63.73
2016-03-31 -373.46 220.98 27.65
2015-12-31 -350.33 214.09 59.07
2015-09-30 -124.57 194.94 32.93
2015-06-30 -115.48 251.53 107.19
2015-03-31 -97.03 222.48 120.84
2014-12-31 -73.77 224.91 120.84
2014-09-30 -40.68 221.27 172.47
2014-06-30 -46.38 186.15 41.21
2014-03-31 17.54 174.05 35.76
2013-12-31 -30.71 250.26 70.79
2013-09-30 -167.72 405.69 93.80
2013-06-30 -152.36 332.38 28.53
2013-03-31 -146.81 332.02 28.01
  • MannKind has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if MannKind's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MannKind has less than a year of cash runway based on current free cash flow.
  • MannKind has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.8% each year.
X
Financial health checks
We assess MannKind's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MannKind has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MannKind's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MannKind dividends.
If you bought $2,000 of MannKind shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MannKind's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MannKind's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:MNKD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:MNKD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MannKind has not reported any payouts.
  • Unable to verify if MannKind's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MannKind's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MannKind has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MannKind's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MannKind afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MannKind has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MannKind's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Castagna
COMPENSATION $1,508,741
AGE 42
TENURE AS CEO 2.8 years
CEO Bio

Dr. Michael E. Castagna, Pharm.D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016 until July 12, 2017 and served as its Corporate Vice President since March 2016. Dr. Castagna leads commercialization efforts for Afrezza. Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna has been Director of MannKind Corporation since May 25, 2017. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington. Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy and his MBA from the Wharton School of Business at the University of Pennsylvania.

CEO Compensation
  • Michael's compensation has increased whilst company is loss making.
  • Michael's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the MannKind management team in years:

3
Average Tenure
55
Average Age
  • The tenure for the MannKind management team is about average.
Management Team

Michael Castagna

TITLE
CEO & Director
COMPENSATION
$2M
AGE
42
TENURE
2.8 yrs

Steven Binder

TITLE
Chief Financial Officer
COMPENSATION
$854K
AGE
56
TENURE
2.7 yrs

David Thomson

TITLE
General Counsel & Secretary
COMPENSATION
$915K
AGE
52
TENURE
18.2 yrs

Pat McCauley

TITLE
Chief Commercial Officer
COMPENSATION
$1M
AGE
53
TENURE
2.7 yrs

David Kendall

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
57
TENURE
2.1 yrs

Joseph Kocinsky

TITLE
Chief Technology Officer
COMPENSATION
$708K
AGE
55
TENURE
4.4 yrs

Rose Alinaya

TITLE
Vice President of Investor Relations & Treasury
COMPENSATION
$520K
AGE
58

Stuart Tross

TITLE
Chief People & Workplace Officer
COMPENSATION
$1M
AGE
52
TENURE
3.3 yrs

John Bedard

TITLE
Senior Vice President of Worldwide Regulatory Affairs
AGE
69
TENURE
14.4 yrs
Board of Directors Tenure

Average tenure and age of the MannKind board of directors in years:

15
Average Tenure
75
Average Age
  • The average tenure for the MannKind board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Kent Kresa

TITLE
Chairman
COMPENSATION
$232K
AGE
81
TENURE
4.1 yrs

Michael Castagna

TITLE
CEO & Director
COMPENSATION
$2M
AGE
42
TENURE
2.8 yrs

Ronald Consiglio

TITLE
Independent Director
COMPENSATION
$205K
AGE
75
TENURE
16.4 yrs

Michael Friedman

TITLE
Independent Director
COMPENSATION
$192K
AGE
75
TENURE
16.3 yrs

Jay Skyler

TITLE
Member of Scientific Advisory Board
AGE
72

Hank Nordhoff

TITLE
Independent Director
COMPENSATION
$185K
AGE
77
TENURE
15 yrs

Julio Rosenstock

TITLE
Member of Scientific Advisory Board

Daniel Porte

TITLE
Member of Scientific Advisory Board

Geremia Bolli

TITLE
Member of Scientific Advisory Board

Steve Edelman

TITLE
Member of Scientific Advisory Board
AGE
63
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by MannKind individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. Feb 20 Buy Steven Binder Individual 31. Jan 20 31. Jan 20 2,168 $0.95 $2,060
03. Feb 20 Buy Stuart Tross Individual 31. Jan 20 31. Jan 20 5,000 $0.95 $4,750
03. Feb 20 Buy James McCauley Individual 31. Jan 20 31. Jan 20 5,000 $0.95 $4,750
03. Feb 20 Buy David Kendall Individual 31. Jan 20 31. Jan 20 2,304 $0.95 $2,189
03. Feb 20 Buy Michael Castagna Individual 31. Jan 20 31. Jan 20 5,000 $0.95 $4,750
01. Aug 19 Buy Steven Binder Individual 31. Jul 19 31. Jul 19 2,139 $0.95 $2,032
01. Aug 19 Buy Stuart Tross Individual 31. Jul 19 31. Jul 19 5,000 $0.95 $4,750
01. Aug 19 Buy James McCauley Individual 31. Jul 19 31. Jul 19 5,000 $0.95 $4,750
01. Aug 19 Buy David Kendall Individual 31. Jul 19 31. Jul 19 5,000 $0.95 $4,750
01. Aug 19 Buy Courtney Barton Individual 31. Jul 19 31. Jul 19 4,011 $0.95 $3,810
01. Aug 19 Buy Michael Castagna Individual 31. Jul 19 31. Jul 19 5,000 $0.95 $4,750
X
Management checks
We assess MannKind's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MannKind has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is MannKind (NASDAQ:MNKD) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. … We note that MannKind Corporation (NASDAQ:MNKD) does have debt on its balance sheet. … NasdaqGM:MNKD Historical Debt, August 1st 2019 How Strong Is MannKind's Balance Sheet?

Simply Wall St -

What Kind Of Investor Owns Most Of MannKind Corporation (NASDAQ:MNKD)?

Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. … We can see that MannKind does have institutional investors; and they hold 27% of the stock. … Private Company Ownership It seems that Private Companies own 11%, of the MNKD stock.

Simply Wall St -

Investors Who Bought MannKind (NASDAQ:MNKD) Shares Five Years Ago Are Now Down 97%

For example, we sympathize with anyone who was caught holding MannKind Corporation (NASDAQ:MNKD) during the five years that saw its share price drop a whopping 97%. … See our latest analysis for MannKind MannKind isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize.

Simply Wall St -

Could The MannKind Corporation (NASDAQ:MNKD) Ownership Structure Tell Us Something Useful?

A look at the shareholders of MannKind Corporation (NASDAQ:MNKD) can tell us which group is most powerful. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned.

Simply Wall St -

Have Insiders Been Buying MannKind Corporation (NASDAQ:MNKD) Shares?

So before you buy or sell MannKind Corporation (NASDAQ:MNKD), you may well want to know whether insiders have been buying or selling. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … In the last twelve months there was more buying than selling by MannKind insiders

Simply Wall St -

Could The MannKind Corporation (NASDAQ:MNKD) Ownership Structure Tell Us Something Useful?

Generally speaking, as a company grows, institutions will increase their ownership. … Our analysis of the ownership of the company, below, shows that. … We can zoom in on the different ownership groups, to learn more about MNKD

Simply Wall St -

Who Owns Most Of MannKind Corporation (NASDAQ:MNKD)?

Today, I will be analyzing MannKind Corporation’s (NASDAQ:MNKD) recent ownership structure, an important but not-so-popular subject among individual investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

Should Your Next Investment Healthcare Be In MannKind Corporation (NASDAQ:MNKD)?

Healthcare analysts are forecasting for the entire industry, a fairly unexciting growth rate of 2.40% in the upcoming year , and a massive growth of 30.34% over the next couple of years. … This rate is larger than the growth rate of the US stock market as a whole. … If MannKind has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

MannKind Corporation (NASDAQ:MNKD): Will The Growth Last?

Today I want to provide a brief commentary on how market analysts perceive MannKind's earnings growth outlook over the next few years and whether the future looks brighter. … View our latest analysis for MannKind Market analysts' consensus outlook for the coming year seems optimistic, with earnings becoming less negative, reaching -US$104.27M in 2019. … The slope of this line is the rate of earnings growth, which in this case is 53.35%.

Simply Wall St -

When Will MannKind Corporation (NASDAQ:MNKD) Turn A Profit?

In this article, I will touch on the expectations for MNKD’s growth and when analysts expect the company to become profitable. … See our latest analysis for MannKind According to the industry analysts covering MNKD, breakeven is near. … So, MNKD is predicted to breakeven approximately 4 years from today.

Simply Wall St -

Company Info

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.

Details
Name: MannKind Corporation
MNKD
Exchange: NasdaqGM
Founded: 1991
$225,033,037
212,295,318
Website: http://www.mannkindcorp.com
Address: MannKind Corporation
30930 Russell Ranch Road,
Suite 300,
Westlake Village,
California, 91362,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MNKD Common Stock Nasdaq Global Market US USD 28. Jul 2004
DB NNFN Common Stock Deutsche Boerse AG DE EUR 28. Jul 2004
Number of employees
Current staff
Staff numbers
232
MannKind employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 01:43
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/17
Last earnings filing: 2020/02/25
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.